Retatrutide pen for sale in Canada — what the 15 mg reloadable 3 mL pen is, how to load, prime, and dose it, how it compares to vials, and where to buy it. Research use only.
The Retatrutide pen is the reloadable 3 mL format of the triple-agonist research compound — a 15 mg payload delivered through a dial-a-dose pen device instead of a draw-up vial. It targets the same GIP, GLP-1, and glucagon receptor axis covered in the Retatrutide research overview, but trades manual reconstitution-and-syringe handling for repeatable dialed doses. This guide covers what the pen is, how to load and use it, how it compares to the vial SKUs, and where the Retatrutide pen is available for sale in Canada.
Retatrutide is a synthetic triple agonist engineered to activate the GIP, GLP-1, and glucagon receptors on a single backbone — the glucagon arm is the mechanistic detail that separates it from dual agonists like Tirzepatide. The pen presentation packages a 15 mg payload into a reloadable 3 mL device. That 15 mg sits deliberately between the 10 mg titration vial and the 20 mg reservoir vial, sized for operators who want the convenience of a dialed dose without committing to the largest format.
The pen is reloadable: you load a reconstituted cartridge, prime the device, dial the dose, and inject — then reload when the cartridge is spent. No drawing up from a vial with a separate syringe each time.
Handled as a research workflow, the sequence is:
Published Phase 2/3 protocols point to once-weekly subcutaneous dosing with gradual titration. As a research compound, the pen is configured for that cadence: continue weekly titration per an established plan rather than jumping to a target dose. The reloadable format makes incremental dialed adjustments simpler than re-drawing from a vial. Always confirm your unit-to-dose conversion against the dosing math guide before dialing.
Store the loaded pen refrigerated and use it within roughly thirty days of loading. Avoid freezing and minimise time at room temperature. The cold chain and shelf life guide covers transport and excursion handling in detail.
The pen and the vials cover the same compound; the difference is handling:
The Retatrutide pen is for sale in Canada as a research-grade compound, priced and shipped in CAD: Retatrutide 15 mg · Pen. If you prefer the vial format, the 10 mg, 20 mg, and 30 mg vials carry the same compound at a lower cost per milligram. All Retatrutide SKUs are sold for research use only.
Is the Retatrutide pen for sale in Canada? Yes. The Retatrutide pen is a 15 mg reloadable 3 mL device available for sale in Canada as a research-grade compound, priced and shipped in CAD. You can order it on the product page.
How much is the Retatrutide pen? The 15 mg Retatrutide pen is listed at CAD $400. The 10 mg, 20 mg, and 30 mg vials are priced lower per SKU if you prefer the draw-up format.
How do I load and use a reloadable peptide pen? Reconstitute the cartridge with bacteriostatic water, seat it in the pen, attach a needle, prime to clear air, dial the prescribed dose, and inject subcutaneously while rotating sites. See the reconstitution and injection-technique guides for step detail.
Retatrutide pen vs vial — what's the difference? Both deliver the same triple-agonist compound. The pen gives repeatable dialed doses and simpler handling; the vials give a lower cost per milligram and flexible volumes. The pen's 15 mg payload sits between the 10 mg and 20 mg vials.
Is the Retatrutide pen research use only? Yes. Every Retatrutide SKU, pen or vial, is supplied strictly for laboratory and research use until accompanied by an applicable prescription. Nothing here is medical advice or a therapeutic claim.
